Edwards Lifesciences Q3 sales rise 9% to $1.35 billion; full-year guidance kept
Edwards Lifesciences reported third-quarter 2024 net sales of $1.35 billion, up 9% from a year earlier, with adjusted EPS of $0.67 versus $0.55. It reiterated its 2024 full-year sales growth guidance of 8% to 10% and gave fourth-quarter sales and EPS ranges. GAAP diluted EPS of $5.13 was driven mainly by a one-time gain from discontinued operations tied to the Critical Care sale.
Key points
- Q3 net sales $1,354.4 million, up 8.9% from $1,243.4 million; TMTT sales up 73%, TAVR up 6%
- Q3 GAAP diluted EPS $5.13 (continuing operations $0.61); adjusted EPS $0.67
- Full-year sales growth guidance of 8% to 10% unchanged; Q4 sales expected at $1.33 to $1.39 billion and Q4 EPS at $0.53 to $0.57
- Repurchased $1.0 billion of stock in Q3; about $1.4 billion remains under authorization
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:42 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 24, 2024.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.